Press Releases

Nov 14, 2022 Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Nov 08, 2022 Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
Nov 04, 2022 Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Oct 24, 2022 Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
Oct 05, 2022 Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
Aug 24, 2022 Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
Aug 09, 2022 Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Jul 20, 2022 Assembly Biosciences Announces Program Reprioritization and Organizational Update
Jun 22, 2022 Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
Jun 21, 2022 Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022